FDA 483 - Nanospectra Bioscience Inc - November 22, 2024

An FDA inspection of Nanospectra Bioscience Inc, a sponsor in Houston, TX, revealed two significant observations. The firm failed to obtain updated financial disclosure information from participating investigators and did not ensure all investigators received consistent versions of the investigational plan. These issues indicate deficiencies in sponsor oversight of clinical investigations.